{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:29:12Z","timestamp":1770902952864,"version":"3.50.1"},"reference-count":22,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1517\/14712598.2014.868433","type":"journal-article","created":{"date-parts":[[2013,12,21]],"date-time":"2013-12-21T05:48:05Z","timestamp":1387604885000},"page":"145-150","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients"],"prefix":"10.1517","volume":"14","author":[{"given":"Joaqu\u00edn","family":"Borr\u00e1s-Blasco","sequence":"first","affiliation":[{"name":"Specialist in Hospital Pharmacy,Hospital de Sagunto, Pharmacy Service","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gracia-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Specialist in Rheumatology,Hospital de Sagunto, Rehabilitation Section","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J Dolores","family":"Rosique-Robles","sequence":"additional","affiliation":[{"name":"Specialist in Hospital Pharmacy,Hospital de Sagunto, Pharmacy Service","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MD Elvira","family":"Caster\u00e1","sequence":"additional","affiliation":[{"name":"Specialist in Hospital Pharmacy,Hospital de Sagunto, Pharmacy Service","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F Javier","family":"Abad","sequence":"additional","affiliation":[{"name":"Specialist in Hospital Pharmacy,Hospital de Sagunto, Pharmacy Service","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2013,12,21]]},"reference":[{"key":"e_1_3_1_2_1","unstructured":"Pfizer Ltd. Enbrel: summary of product characteristics"},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30115"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10123"},{"key":"e_1_3_1_5_1","first-page":"238","article-title":"Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis","volume":"29","author":"Klareskog L","year":"2011","unstructured":"Klareskog L, Gaubitz M, Rodr\u00edguez-Valverde V, et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:238-47","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4244"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462311000195"},{"key":"e_1_3_1_8_1","first-page":"S120","article-title":"The effects of low dose etanercept on disease control and radiographic progression in moderate to severe rheumatoid arthritis","volume":"62","author":"Raffeiner B","year":"2010","unstructured":"Raffeiner B, Botsios C, Sfriso P, et al. The effects of low dose etanercept on disease control and radiographic progression in moderate to severe rheumatoid arthritis. Arthritis Rheum 2010;62:S120","journal-title":"Arthritis Rheum"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S31474"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126573"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200350"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.03.010"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.01.002"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61811-X"},{"key":"e_1_3_1_18_1","first-page":"54","article-title":"Effects of low-dose etanercept in maintaining das-remission previously achieved with standard-dose in patients with rheumatoid arthritis","volume":"66","author":"Botsios C","year":"2009","unstructured":"Botsios C, Furlan A, Otsuni P, et al. Effects of low-dose etanercept in maintaining das-remission previously achieved with standard-dose in patients with rheumatoid arthritis. Ann Rheum Dis 2009;66(Suppl II):54","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1722-5"},{"key":"e_1_3_1_20_1","article-title":"Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients","author":"De Stefano R","year":"2013","unstructured":"De Stefano R, Frati E, De Quattro D, et al. Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients. Clin Rheumatol 2013.[Epub ahead of print]","journal-title":"Clin Rheumatol"},{"key":"e_1_3_1_21_1","article-title":"Reduction of biological agent dose in rheumatic diseases: Descriptive analysis of 153 patients in clinical practice conditions","author":"Inciarte-Mundo J","year":"2013","unstructured":"Inciarte-Mundo J, Hern\u00e1ndez MV, Rosario V, et al. Reduction of biological agent dose in rheumatic diseases: Descriptive analysis of 153 patients in clinical practice conditions. Reumatol Clin 2013.[Epub ahead of print]","journal-title":"Reumatol Clin"},{"key":"e_1_3_1_22_1","unstructured":"Navarro-Comp\u00e1n V Moreira Navarrete V Ariza Ariza R et al. Costes farmacol\u00f3gicos asociados al ajuste de dosis de etanercept en pacientes con espondilitis anquilosante en remisi\u00f3n. 56 Congreso SEFH; 2011"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1130-6343(07)75718-5"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14712598.2014.868433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:36:56Z","timestamp":1770899816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14712598.2014.868433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,21]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1517\/14712598.2014.868433"],"URL":"https:\/\/doi.org\/10.1517\/14712598.2014.868433","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2013-12-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}